Efficacy, Safety and PK/PD of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN) (NewPLACE)
Status:
Recruiting
Trial end date:
2024-01-11
Target enrollment:
Participant gender:
Summary
This 2-arm, multi-center, open-label, parallel-group phase II trial will assess the efficacy,
safety and pharmacokinetics/pharmacodynamics of the human antibody MOR202 in subjects with
anti-PLA2R antibody-positive membranous nephropathy indicated for immunosuppressive therapy